Prelude Capital Management, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $2,394 - $3,686	-300 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $2,388 - $3,726	300 New	300 $2,000
Q1 2020 May 15, 2020	SELL	$4.91 - $14.7 $6,775 - $20,286	-1,380 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$9.77 - $15.66 $1,289 - $2,067	-132 Reduced 8.73%	1,380 $21,000
Q3 2019 Nov 14, 2019	BUY	$9.59 - $12.0 $13,119 - $16,416	1,368 Added 950.0%	1,512 $15,000

Q2 2019 Aug 14, 2019	SELL	$9.54 - $14.96 $11,247 - $17,637	-1,179 Reduced 89.12%	144 $2,000
Q1 2019 May 15, 2019	SELL	$10.31 - $14.38 $149,041 - $207,877	-14,456 Reduced 91.62%	1,323 $18,000
Q4 2018 Feb 14, 2019	SELL	$8.63 - $12.4 $113,700 - $163,370	-13,175 Reduced 45.5%	15,779 $160,000
Q3 2018 Nov 14, 2018	BUY	$9.6 - $12.9 $277,958 - $373,506	28,954 New	28,954 $347,000
Q4 2017 Feb 14, 2018	SELL	$10.5 - $14.15 $30,450 - $41,035	-2,900 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$7.7 - $11.55 $22,330 - $33,495	2,900	2,900 $32,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $496M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.